Compare Amphastar Pharmaceuticals Inc (AMPH) vs Crown Castle International Corp (CCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Crown Castle International Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Crown Castle International Corp trades at $80 (market cap $34.77B). The key difference: Crown Castle International Corp is far larger — about 42.1× Amphastar Pharmaceuticals Inc's market cap, and Crown Castle International Corp pays a 5.34% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CCI | |
|---|---|---|
Market Cap | $826.08M | $34.77B |
Sector | Health | Real Estate |
52-Week High | $30.81 | $113.91 |
52-Week Low | $16.87 | $74.92 |
Enterprise Value | $1.22B | $64.59B |
Dividend Yield | — | 5.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Crown Castle (CCI) trades at $79.66, up 3.89% today, but remains in a bearish technical trend with weak moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, while revenue declined to $4.26B in 2025. Analyst consensus is divided with a $97.33 price target, and the stock offers a 5.55% dividend yield. Recent news highlights strategic shifts to a pure-play tower focus amid leadership changes.
Outlook is cautious due to high debt levels and competitive pressures, but long-term value exists if operational improvements materialize. Key risks include interest rate sensitivity and execution challenges. Investors should weigh the dividend appeal against fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
